Recursive’s $400 million outlay represents the bulk of the company’s fundraising to date.

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Michael Boyle is an experienced financial professional with more than 10 years working with financial planning, derivatives, equities, fixed income, project management, and analytics. Amanda Jackson ...

Marshall Hargrave is a stock analyst and writer with 10+ years of experience covering stocks and markets, as well as analyzing and valuing companies. Thomas J Catalano is a CFP and Registered ...

Jay Clayton, President Trump’s nominee to head the nation’s intelligence agencies, clashed with Democrats during his confirmation hearing this week. It was the latest example of members of the ...